Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients
On Saturday, Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
At the time of this analysis, the Braftovi combination regimen demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) compared to patients receiving chemotherapy with or without bevacizumab (60.9% vs. 40.0%).
Also Read:
The results were presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI) and were simultaneously published in Nature Medicine.
The estimated median duration of response was 13.9 months with Braftovi plus cetuximab and mFOLFOX6 and 11.1 months with chemotherapy with or without bevacizumab.
Of patients on Braftovi plus cetuximab and mFOLFOX6, 22.4% (n=15) had a response lasting 12 months or longer, compared to 11.4% (n=5) with chemotherapy with or without bevacizumab.
The median time to response was 7.1 weeks with Braftovi plus cetuximab and mFOLFOX6 and 7.3 weeks with chemotherapy with or without bevacizumab.
Overall survival (OS) data were immature during this analysis but demonstrated a trend favoring Braftovi plus cetuximab and mFOLFOX6 compared to patients receiving chemotherapy with or without bevacizumab.
Median overall survival with Braftovi plus cetuximab with chemotherapy was not estimable, and 14.6 months with chemotherapy with or without bevacizumab.
The BREAKWATER trial is ongoing for OS and progression-free survival (PFS), with PFS results expected in 2025.
The safety profile of Braftovi in combination with cetuximab and mFOLFOX6 in the BREAKWATER trial was consistent with the known safety profile of each respective agent. No new safety signals were identified.
In December 2024, the FDA granted accelerated approval to Braftovi in combination with cetuximab and mFOLFOX6 for BRAF V600E-mutant mCRC.
Price Action: PFE stock is up 2.76% at $26.81 at the last check on Monday.
Read Next:Image via Shutterstock
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
PFIZER (PFE): Free Stock Analysis Report
This article Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
32 minutes ago
- Business Wire
BF-A, BF-B Investors Have Opportunity to Join Brown-Forman Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brown-Forman Corporation ('Brown-Forman' or 'the Company') (NYSE: BF-A, BF-B) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Brown-Forman reported its financial results for fiscal year 2025 on June 5, 2025. The Company reported a decline in year-over-year sales of 7.3% and earnings per share below consensus estimates. The Company stated its "results did not meet our long-term growth aspirations," and advised investors that "looking ahead to fiscal 2026, we expect continued headwinds." If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
an hour ago
- Yahoo
Why The Mosaic Company (MOS) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where The Mosaic Company (NYSE:MOS) stands against other Friday's worst-performing stocks. Shares of The Mosaic Company decreased by 4.40 percent on Friday to end at $34.80 apiece, a third straight day, as investors reacted negatively to lower production guidance for the second quarter and full year 2025. In a statement, The Mosaic Company (NYSE:MOS) said it now sees phosphate sales volumes for the second quarter of 2025 to be in the range of 1.5 million to 1.6 million tons, or lower than the 1.7 million to 1.9 million tons as targeted previously. A farmer tending to his crops in a field, with a fertiliser bag nearby. It also revised its production guidance for the full year period to 7 million to 7.3 million tons, lower than the 7.2 million to 7.6 million tons as expected previously. While its phosphate facility in New Wales was expected to increase over 20 percent in the current quarter, commissioning and ramp-up of the first of three new gypsum handling systems took longer than expected. The Mosaic Company (NYSE:MOS) said it now expects the second and third systems to be installed and commissioned by the end of June and early July. Additionally, it extended planned downtimes for its Riverview facility to eliminate bottlenecks, causing production to miss initial expectations. Its Louisiana facilities also discovered additional necessary repairs, resulting in extended outage periods and some lost production. Overall, MOS ranks 8th on our list of Friday's worst-performing stocks. While we acknowledge the potential of MOS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Why Fortuna Mining Corp. (FSM) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where Fortuna Mining Corp. (NYSE:FSM) stands against other Friday's worst-performing stocks. Fortuna Mining dropped its share prices by 3.65 percent on Friday to finish at $7.13 apiece as investors resorted to profit-taking following the previous day's gains. Fortuna Mining Corp. (NYSE:FSM), a leading gold and silver mining company, earned a boost from higher gold and silver prices on Thursday, with the latter hitting a new all-time high. Aerial view of miners extracting precious metal deposits in a quarry. Friday, however, saw spot prices of gold drop by 1.26 percent, while silver maintained its strength with another 0.92 percent gain. In the first quarter of the year, Fortuna Mining Corp. (NYSE:FSM) grew its net income from continuing operations by 130 percent to $67.97 million from $29.5 million in the same period last year. Sales rose by 45 percent to $290 million from $200.9 million year-on-year. Fortuna Mining Corp. (NYSE:FSM) is expected to hold an annual shareholders' meeting at 10 AM PDT on June 26 in Vancouver, Canada. Overall, FSM ranks 10th on our list of Friday's worst-performing stocks. While we acknowledge the potential of FSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
